Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
P-CD19CD20-ALLO1 Cells · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Participants will receive a lymphodepleting chemotherapy regimen followed by a single infusion of P-CD19CD20-ALLO1. Dose escalation decisions will be made after participants are observed for a minimum of 28 days for toxicity. |
| Name | Type | Description |
|---|---|---|
| P-CD19CD20-ALLO1 Cells | BIOLOGICAL | P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol. |
| Cyclophosphamide | DRUG | Cyclophosphamide will be administered intravenously. |
| Fludarabine | DRUG | Fludarabine will be administered intravenously. |
Inclusion Criteria: * Age 18-60 years (inclusive) at the time of signing Informed Consent Form * Diagnosis of progressive MS according to the revised McDonald 2017 criteria, and: Expanded disability status scale (EDSS) score at screening, from 3 to 6 inclusive Evidence of disability progression an...
P-CD19CD20-ALLO1 Cells is an investigational cell therapy being studied for the treatment of Multiple Sclerosis. It is currently in Phase 1 clinical development, with an active clinical trial evaluating its safety, tolerability, cellular kinetics, and pharmacodynamics in participants with Multiple Sclerosis.
P-CD19CD20-ALLO1 Cells is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 1 clinical trial of this investigational therapy in the United States for Multiple Sclerosis.
P-CD19CD20-ALLO1 Cells is in Phase 1 clinical development. It is an investigational therapy, not yet approved, and is being studied in an active clinical trial for Multiple Sclerosis. The trial is currently active but not recruiting participants.
P-CD19CD20-ALLO1 Cells is being evaluated in a Phase 1 clinical trial with the identifier NCT07008378. This study is assessing the safety, tolerability, cellular kinetics, and pharmacodynamics of the therapy in participants with Multiple Sclerosis. The trial is active but not recruiting, with an enrollment of 60 participants.
P-CD19CD20-ALLO1 Cells is not FDA approved. It is an investigational therapy currently in Phase 1 clinical development for Multiple Sclerosis. The ongoing clinical trial is designed to evaluate its safety and other characteristics, but it has not yet received regulatory approval.